- Home
- LPG vs EOLS Comparison
LPG vs EOLS Comparison
Compare LPG & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPG
- EOLS
- Stock Information
- Founded
- LPG 2013
- EOLS 2012
- Country
- LPG United States
- EOLS United States
- Employees
- LPG N/A
- EOLS N/A
- Industry
- LPG Marine Transportation
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- LPG Consumer Discretionary
- EOLS Health Care
- Exchange
- LPG Nasdaq
- EOLS Nasdaq
- Market Cap
- LPG 913.3M
- EOLS 854.0M
- IPO Year
- LPG 2014
- EOLS 2018
- Fundamental
- Price
- LPG $22.35
- EOLS $12.03
- Analyst Decision
- LPG Strong Buy
- EOLS Strong Buy
- Analyst Count
- LPG 1
- EOLS 4
- Target Price
- LPG $35.00
- EOLS $24.67
- AVG Volume (30 Days)
- LPG 783.7K
- EOLS 710.0K
- Earning Date
- LPG 05-21-2025
- EOLS 03-04-2025
- Dividend Yield
- LPG 16.56%
- EOLS N/A
- EPS Growth
- LPG N/A
- EOLS N/A
- EPS
- LPG 3.87
- EOLS N/A
- Revenue
- LPG $416,947,918.00
- EOLS $266,274,000.00
- Revenue This Year
- LPG N/A
- EOLS $34.56
- Revenue Next Year
- LPG $10.11
- EOLS $32.26
- P/E Ratio
- LPG $5.78
- EOLS N/A
- Revenue Growth
- LPG N/A
- EOLS 31.76
- 52 Week Low
- LPG $19.36
- EOLS $9.25
- 52 Week High
- LPG $51.66
- EOLS $17.82
- Technical
- Relative Strength Index (RSI)
- LPG 49.87
- EOLS 35.16
- Support Level
- LPG $20.00
- EOLS $11.59
- Resistance Level
- LPG $23.85
- EOLS $13.66
- Average True Range (ATR)
- LPG 0.67
- EOLS 0.55
- MACD
- LPG 0.12
- EOLS -0.15
- Stochastic Oscillator
- LPG 58.65
- EOLS 21.26
About LPG Dorian LPG Ltd.
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.